SCHEMBL21709439

SCHEMBL21709439

c1ccc(-c2ccc(N(c3ccc(-c4ccccc4)cc3)c3nc(-c4ccccc4)c4ccccc4n3)cc2)cc1

nearest known ligand 0.63

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NUDT1 P36639 3/20 0.63
ADORA2A P29274 4/20 0.50
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
ATM Q13315 1/20 0.47
MAPT P10636 3/20 0.46
GAA P10253 1/20 0.46
SCN9A Q15858 2/20 0.46
ALDH1A1 P00352 4/20 0.45
KDM4E B2RXH2 3/20 0.45
HPGD P15428 2/20 0.45
NPSR1 Q6W5P4 1/20 0.45
LMNA P02545 2/20 0.43
HTT P42858 1/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
RAD52 P43351 1/20 0.43
DHODH Q02127 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24255950 1.00 NUDT1 (0.63) NUDT1ADORA2AMEN1KMT2AATM
SCHEMBL23605079 0.98 NUDT1 (0.61) NUDT1ADORA2AMEN1KMT2AATM
SCHEMBL24255933 0.89 NUDT1 (0.51) NUDT1ADORA2AMEN1KMT2AATM
SCHEMBL22079049 0.88 NUDT1 (0.49) NUDT1ADORA2AMEN1KMT2AATM
SCHEMBL23605059 0.85 NUDT1 (0.50) NUDT1ADORA2AMEN1KMT2AATM
SCHEMBL24255929 0.83 NUDT1 (0.45) NUDT1ADORA2AMEN1KMT2AATM
SCHEMBL24255932 0.83 NUDT1 (0.45) NUDT1ADORA2AMEN1KMT2AATM
SCHEMBL21709371 0.83 NUDT1 (0.45) NUDT1ADORA2AMEN1KMT2AATM
SCHEMBL21709426 0.82 MEN1 (0.67) NUDT1ADORA2AMEN1KMT2AATM
SCHEMBL26571591 0.82 MEN1 (0.67) NUDT1ADORA2AMEN1KMT2AATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200048207-A1 COMPOUNDS WITH ARYLAMINE STRUCTURES MERCK PATENT GMBH (DE) 2020-02-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200048207-A1 COMPOUNDS WITH ARYLAMINE STRUCTURES DDT, NAT1, INMT NUDT1 15/4885ADORA2A 319/4885MEN1 2014/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.